secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006240
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q4 2022 net loss of $34.4M; cash runway into 2025; reiterates pipeline milestones
--------------------------------------------------------------------------------

- Net loss of $34.4M for Q4 2022 ($141.9M full year) vs $37.4M Q4 2021.
- Cash and equivalents $242.7M as of Dec 31, 2022; expected to fund operations into 2025.
- R&D expenses $28.5M in Q4 2022 ($112.5M full year) vs $27.2M Q4 2021.
- Phase 2 trial of ANX007 in geographic atrophy on track for initial data mid-2023.
- Phase 1 MAD trial of ANX1502 initiated; proof-of-concept in CAD planned for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023006240/0000950170-23-006240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023006240/annx-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer